A Look At Xeris Biopharma Holdings (XERS) Valuation As It Fights To Protect Recorlev Exclusivity [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Xeris Biopharma Holdings (XERS) has filed a patent infringement lawsuit to block Torrent Pharmaceuticals and Somerset Therapeutics from producing generic versions of Recorlev. This move raises questions about future exclusivity and potential effects on investor sentiment. See our latest analysis for Xeris Biopharma Holdings. The lawsuit news follows a sharp 9.2% one-day share price decline and a 16.7% year-to-date share price pullback. However, the 1-year total shareholder return of about 59.8% and 3-year total shareholder return of a little over 3x suggest longer-term momentum has been strong. The recent weakness may hint at a reassessment of risk ahead of upcoming earnings and legal milestones. If legal and earnings headlines around Xeris have your attention, it could be a suitable time to look at other healthcare names as well, starting with our screen of 27 healthcare AI stocks as potential ideas. With shares now at US$6.12 and trading at a sizable discount to the US$11.1
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]Seeking Alpha
- Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
XERS
Earnings
- 3/2/26 - Beat
XERS
Sec Filings
- 3/2/26 - Form 144
- 3/2/26 - Form S-8
- 3/2/26 - Form 10-K
- XERS's page on the SEC website